FDA Grants Fast Track Designation to Perspective Therapeutics' FAP-Targeted Radiopharmaceutical for Rare Cancer
Event summary
- FDA granted Fast Track Designation to Perspective Therapeutics' [212Pb]PSV359 for treating locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs).
- PSV359 is an investigational FAP-targeted alpha-particle therapy currently in a Phase 1/2a study for advanced FAP-positive solid tumors.
- SFT is a rare cancer with limited treatment options for patients with locally advanced unresectable or metastatic disease.
- The Fast Track Designation may expedite development and review, potentially qualifying PSV359 for rolling review, Accelerated Approval, or Priority Review.
The big picture
The FDA's Fast Track Designation for PSV359 underscores the unmet medical need in treating rare cancers like SFT. Perspective Therapeutics' focus on FAP-targeted alpha-particle therapy aligns with broader industry trends toward precision oncology and radiopharmaceutical innovations. The designation could accelerate the development of PSV359, potentially offering a new treatment option for patients with limited therapeutic choices.
What we're watching
- Clinical Development
- The pace at which Perspective Therapeutics advances PSV359 through clinical trials and secures additional regulatory milestones.
- Market Opportunity
- Whether PSV359 can address the substantial patient population across multiple cancer types expressing FAP-α.
- Competitive Landscape
- How Perspective Therapeutics positions PSV359 against existing and emerging therapies for rare and aggressive cancers.
Related topics